Cannabinoids

Here, we bring you our top four recent articles covering research on cannabinoids and sleep, why enrolled patients turn to illegal cannabis, using spent hemp biomass as livestock feed, and testing cannabinoids on breath after ingesting edibles.

In the second part of this webinar coverage, Dustin Sulak, DO, explains recent research and studies on cannabinoids and their effect on sleep and conditions affecting sleep.

The results from the in vivo animal study also suggest sex-specific responses to cannabinol (CBN).

The results highlight gender disparities, uncertainty about vape contents, and the growing use of synthetic products.

A recent study found that CBD gummies may not have accurate labeling on how much the cannabinoid it contains.

Here, we bring you our top five recent articles covering safety regulations in North Carolina, licenses in Minnesota, the FDA’s FY2026 Agriculture appropriations bill, cannabis taxes in California, and antifungal properties of CBD and CBDV.

Several cease and desist letters were sent to companies in regard to hemp products containing THCA that potentially violate the Missouri Merchandising Practices Act.

The WSWA recently announced support removing a section of the FY2026 Agriculture–FDA appropriations bill, which includes the ability to place a federal ban on naturally-derived cannabinoids.

The cannabinoids cannabidiol (CBD) and cannabidivarin (CBDV) showed antifungal activity in both in vivo tests and in vitro wound models.

The study also identified a new cannabinoid in the plant, named cannabielsoxa.

Here, we bring you our top four recent articles covering the cost of compliance in the industry, the role of lighting in indoor cultivation, and research involving cannabis ointment and cannabis-coated pillowcases.

The ointment containing CBD and CBG was evaluated for its effect on improvements in symptoms after an eight week period.

GVB Biopharma announced their new CBT Isolate product.

This survey assesses consumer awareness, usage patterns, and safety concerns with results indicating that cannabidiol (CBD), Δ8-tetrahydrocannabinol (Δ8-THC), and cannabinol (CBN) are the most frequently used cannabinoids, with vapes and edibles being the preferred methods of consumption.

Nanoemulsion technology is poised to play a pivotal role in the future of cannabinoid delivery as it helps address challenges related to the solubility, bioavailability, and stability of cannabinoids.

The December webinar from Healer featured several studies on various conditions treated with medical cannabis.

Here, Scott Mazza, Founder of Vitality CBD, provides an overview on the potential benefits of minor cannabinoids including cannabinol (CBN) and cannabingerol (CBG).

This article examines what rescheduling cannabis would involve, the implications for various sectors, and the potential roadblocks that could arise along the way.

The bill regulates the sale and distribution of products containing synthetic THC, though some challenges remain to be resolved.

Products containing Delta-8 THC may be leading to an increase in calls to poison control centers, according to a recent study.

A recent study targeting mild to moderate anxiety disorders showed that oral CBD can be a safe, effective treatment option.

This article provides an analysis of current regulations and proposed changes that could impact the hemp industry.

Missouri’s Department of Health and Senior Services is on track to “embargo and condemn” products that contain intoxicating cannabinoids starting September 1, 2024 in accordance to an executive order signed by the state’s governor, Michael L. Parsons.

This month’s Healer webinar provided a deep dive into several studies on cannabis for various conditions.

This presentation provided a comprehensive overview of cannabigerol (CBG), highlighting two studies on its effects on anxiety, stress, and pain.